• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Ivermectin as a potential therapeutic in COVID-19.伊维菌素作为治疗新冠肺炎的一种潜在疗法。
Clin Pharmacol Transl Med. 2020;4(1):160-161. Epub 2020 Dec 29.
2
Prophylactic Role of Ivermectin in Severe Acute Respiratory Syndrome Coronavirus 2 Infection Among Healthcare Workers.伊维菌素在医护人员严重急性呼吸综合征冠状病毒2感染中的预防作用
Cureus. 2021 Aug 5;13(8):e16897. doi: 10.7759/cureus.16897. eCollection 2021 Aug.
3
Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching.用于COVID-19的伊维菌素预防：一项对223,128名受试者进行倾向评分匹配的全市前瞻性观察研究。
Cureus. 2022 Jan 15;14(1):e21272. doi: 10.7759/cureus.21272. eCollection 2022 Jan.
4
Ivermectin treatment for infection in patients with COVID-19.伊维菌素治疗新型冠状病毒肺炎患者的感染情况。
Can Commun Dis Rep. 2021 Jul 8;47(7-8):316-321. doi: 10.14745/ccdr.v47i78a04.
5
Development of a Minimal Physiologically-Based Pharmacokinetic Model to Simulate Lung Exposure in Humans Following Oral Administration of Ivermectin for COVID-19 Drug Repurposing.开发一种最小生理基于药代动力学模型，以模拟新冠肺炎药物再利用中经口给予伊维菌素后人体肺部的暴露情况。
J Pharm Sci. 2020 Dec;109(12):3574-3578. doi: 10.1016/j.xphs.2020.08.024. Epub 2020 Sep 4.
6
A COVID-19 prophylaxis? Lower incidence associated with prophylactic administration of ivermectin.一种 COVID-19 预防药物？伊维菌素预防性给药与较低的发病率相关。
Int J Antimicrob Agents. 2021 Jan;57(1):106248. doi: 10.1016/j.ijantimicag.2020.106248. Epub 2020 Nov 28.
7
Self-prescribed Ivermectin use is associated with a lower rate of seroconversion in health care workers diagnosed with COVID, in a dose-dependent response.自我处方伊维菌素的使用与 COVID 确诊医护人员的血清转化率降低有关，且呈剂量依赖性反应。
Braz J Infect Dis. 2021 Jul-Aug;25(4):101603. doi: 10.1016/j.bjid.2021.101603. Epub 2021 Aug 12.
8
Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A single-centre randomized, placebo-controlled trial.单剂量口服伊维菌素治疗轻中度 COVID-19（RIVET-COV）：一项单中心随机、安慰剂对照试验。
J Infect Chemother. 2021 Dec;27(12):1743-1749. doi: 10.1016/j.jiac.2021.08.021. Epub 2021 Aug 25.
9
Chemoprophylaxis against COVID-19 among health-care workers using Ivermectin in low- and middle-income countries: A systematic review and meta-analysis.伊维菌素用于中低收入国家医护人员的 COVID-19 化学预防：系统评价和荟萃分析。
Indian J Pharmacol. 2021 Nov-Dec;53(6):493-498. doi: 10.4103/ijp.ijp_117_21.
10
The association between the use of ivermectin and mortality in patients with COVID-19: a meta-analysis.伊维菌素的使用与 COVID-19 患者死亡率之间的关联：一项荟萃分析。
Pharmacol Rep. 2021 Oct;73(5):1473-1479. doi: 10.1007/s43440-021-00245-z. Epub 2021 Mar 29.

本文引用的文献

1
Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19.伊维菌素可能是一种对晚期新冠肺炎有临床实用价值的抗炎药。
Open Heart. 2020 Sep;7(2). doi: 10.1136/openhrt-2020-001350.
2
Coronavirus reinfections: three questions scientists are asking.新冠病毒再次感染：科学家们正在探讨的三个问题。
Nature. 2020 Sep;585(7824):168-169. doi: 10.1038/d41586-020-02506-y.
3
Ivermectin Docks to the SARS-CoV-2 Spike Receptor-binding Domain Attached to ACE2.伊维菌素与附着在 ACE2 上的 SARS-CoV-2 刺突受体结合域结合。
In Vivo. 2020 Sep-Oct;34(5):3023-3026. doi: 10.21873/invivo.12134.
4
COVID-19 Therapeutic Options Under Investigation.正在研究的COVID-19治疗方案。
Front Pharmacol. 2020 Aug 6;11:1196. doi: 10.3389/fphar.2020.01196. eCollection 2020.
5
White paper on Ivermectin as a potential therapy for COVID-19.关于伊维菌素作为新冠病毒潜在疗法的白皮书。
Indian J Tuberc. 2020 Jul;67(3):448-451. doi: 10.1016/j.ijtb.2020.07.031.
6
Nicotine and the nicotinic cholinergic system in COVID-19.尼古丁和 COVID-19 中的烟碱型乙酰胆碱能系统。
FEBS J. 2020 Sep;287(17):3656-3663. doi: 10.1111/febs.15521. Epub 2020 Aug 25.
7
Genomic variance of Open Reading Frames (ORFs) and Spike protein in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）的开放阅读框（ORFs）和刺突蛋白的基因组变异。
J Chin Med Assoc. 2020 Aug;83(8):725-732. doi: 10.1097/JCMA.0000000000000387.
8
"COVID-19: diagnosis, management and prognosis": a new topical collection of Internal and Emergency Medicine.《“COVID-19：诊断、管理与预后”》：内科学与急诊医学新的专题文集
Intern Emerg Med. 2020 Aug;15(5):747-750. doi: 10.1007/s11739-020-02461-6. Epub 2020 Jul 30.
9
A nicotinic hypothesis for Covid-19 with preventive and therapeutic implications.一种与 COVID-19 相关的烟碱能假说及其预防和治疗意义。
C R Biol. 2020 Jun 5;343(1):33-39. doi: 10.5802/crbiol.8.
10
COVID-19 and the rush for self-medication and self-dosing with ivermectin: A word of caution.新冠疫情与自行服用伊维菌素进行自我治疗和自我给药的热潮：一句警示之言。
One Health. 2020 Jun 24;10:100148. doi: 10.1016/j.onehlt.2020.100148. eCollection 2020 Dec.

Ivermectin as a potential therapeutic in COVID-19.

作者信息

Segura-Aguilar Juan, Tizabi Yousef

机构信息

Molecular & Clinical Pharmacology, ICBM, Faculty of Medicine, University of Chile, Chile.

Department of Pharmacology, Howard University College of Medicine, Washington, DC, United States.

出版信息

Clin Pharmacol Transl Med. 2020;4(1):160-161. Epub 2020 Dec 29.

PMID:33778414
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7993655/
Abstract
摘要